PTC Q2 Swings to Profit, Revenue Rises; Ups Guidance
MT Newswires Live
Jul 31
PTC Therapeutics (PTCT) reported a Q2 net income late Thursday of $0.92 per diluted share, swinging from a loss of $0.83 a year earlier.
Analysts polled by FactSet expected $0.24.
Total revenue for the quarter ended June 30 rose to $360.5 million from $178.9 million a year earlier.
Analysts expected $298.6 million.
For 2026, the company now expects total revenue of $1.18 billion to $1.28 billion, up from its prior guidance of $1.08 billion to $1.18 billion. Analysts expect $1.18 billion.
Shares were up over 2% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.